Multisystem Monitoring and Coordination of Hypoparathyroidism Care

Dr. Shoback describes a structured but individualized approach. She manages biochemical monitoring and symptom assessment herself, referring patients to ophthalmology every one to two years and to neurology when neuromuscular complaints are significant. She performs renal imaging and 24-hour urine monitoring approximately annually and tailors bone density assessment to the patient's age, baseline findings, and fracture history. Any complication outside the endocrine domain is referred to the appropriate specialist. For patients with genetic etiologies, multidisciplinary input from cardiologists, dental providers, and immunologists may all be needed.

When asked about lesser-known or commonly overlooked symptoms, Dr. Shoback highlights dental abnormalities arising from impaired dental development in early-onset disease, early cataracts in patients who had severe calcium disturbance in childhood, and seizure disorders. She notes that clinicians focused primarily on biochemical optimization may miss these manifestations.

Dr. Cusano then asks when Dr. Shoback refers to other specialties versus managing manifestations herself. Dr. Shoback explains she retains biochemical monitoring and bone density surveillance, but escalates to urology when a patient passes a kidney stone, to nephrology when renal function declines meaningfully, and to neurology for significant neuromuscular complaints. She underscores that the referral threshold is individualized and depends on how the patient is doing, but that multidisciplinary care is the rule rather than the exception in complex cases. She transitions the discussion toward the goals of treatment, noting that the optimal framework for managing hypoparathyroidism must be grounded in clear clinical targets.

In the next episode, "Goals of Treatment and Special Considerations in Hypoparathyroidism," Dr. Ferenczi outlines the six consensus-based goals of hypoparathyroidism treatment and explains why autosomal dominant hypocalcemia type 1 requires a distinctly different and more conservative therapeutic approach.